𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evaluation of nutritional indices as prognostic indicators in the cancer patient

✍ Scribed by John M. Daly; Stanley J. Dudrick; Edward M. Copeland Iii

Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
637 KB
Volume
43
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Evaluations of interferon-Ξ³/interleukin-
Evaluations of interferon-Ξ³/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients
✍ Hideyuki Ubukata; Gyou Motohashi; Takanobu Tabuchi; Hiroyuki Nagata; Satoru Koni πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 318 KB

## Abstract ## Background and Objectives Th2‐dominant immunity and high neutrophil/lymphocyte ratios (NLRs) have been reported to reflect tumor progression, and so we examined whether the Th1/Th2 ratio and NLR can act as prognostic indicators or not. ## Methods Peripheral blood samples were take

Immunofluorometrically determined p53 ac
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients
✍ Michael A. Levesque; Dionyssios Katsaros; He Yu; Maurizia Giai; Franco Genta; Ri πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 82 KB

The prognostic value of p53 protein accumulation in breast cancer, especially as detected by methods other than immunohistochemistry, has not been established unequivocally. A sensitive immunofluorometric assay of p53 protein employing DO-1 and CM-1 antibodies was used in this study to assay extract

Evaluation of a displacement assay with
Evaluation of a displacement assay with tamoxifen as prognostic indicator in breast-cancer patients with estrogen-receptor-positive tumors
✍ Emanuel Levin; Andrea M. Actis; Silvana Caruso; Hugo Gass; Raquel Romero; NicolΓ‘ πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 95 KB πŸ‘ 2 views

A displacement assay with tamoxifen, based on the relative binding affinity of tamoxifen and estradiol for the estrogen receptor (ER), was proposed in 1990 as prognostic indicator for breast-cancer patients. Validation of its predictive results in relation to the outcome of 73 patients with ER Ψ‰ tum